Chemoimmunotherapy.
Chemoimmunotherapy.
复制标题
DOI：
10.1097/ppo.0b013e3181eb5066
复制
发表时间：
2010-07
期刊：
影响因子：
--
通讯作者：
Emens LA
中科院分区：
文献类型：
--
作者：
Emens LA
癌症化疗药物由于其骨髓抑制作用而历来被认为对免疫力有害。然而，越来越多的数据表明，常规癌症化疗的抗肿瘤活性部分来自其通过诱导免疫活性肿瘤细胞死亡来利用先天性和适应性免疫系统的能力。其他数据扩大了癌症化疗药物的免疫学影响，表明某些药物能够以取决于药物剂量及其与免疫治疗相关的给药时间的方式破坏免疫抑制和免疫耐受途径。了解化疗药物和免疫系统之间相互作用的细胞和分子基础将促进化学免疫疗法治疗方案的战略发展，这些治疗方案最大化肿瘤消退和抗肿瘤免疫应答，从而使癌症患者获得长期临床益处。
Cancer chemotherapy drugs are historically regarded as detrimental to immunity due to their myelosuppressive effects. However, accumulating data suggest that the antitumor activity of conventional cancer chemotherapy results in part from its ability to harness the innate and adaptive immune systems by inducing immunologically active tumor cell death. Additional data broaden the immunologic impact of cancer chemotherapy drugs, demonstrating that some drugs have the ability to disrupt pathways of immune suppression and immune tolerance in a manner that depends on the drug dose, and the timing of its administration in relation to immunotherapy. Understanding the cellular and molecular basis of the interactions between chemotherapy drugs and the immune system will facilitate the strategic development of chemoimmunotherapy treatment regimens that both maximize tumor regression and the antitumor immune response for the long term clinical benefit of cancer patients.